Literature DB >> 12198606

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

Gloria Y F Ho1, Yevgeniy Studentsov, Charles B Hall, Robert Bierman, Leah Beardsley, Michele Lempa, Robert D Burk.   

Abstract

A high incidence of initial infection with human papillomavirus (HPV) was previously reported in a cohort of 608 women monitored at 6-month intervals for 3 years. Risk factors for subsequent infections with different HPV types and whether antibodies against HPV-16 virus-like particles (VLPs) protected against these infections were examined. Subsequent infections with HPV are very common. Seventy percent of women acquired a different HPV type within 24 months of the initial infection. Risk factors included being nonwhite, having an increased number of male sex partners, and having had a new male sex partner. Use of oral contraceptive pills was protective. A sustained high level of IgG antibody to HPV-16 VLPs was associated with reduced risk for subsequent infection with HPV-16 and its genetically related types (i.e., HPV-31, -33, -35, -52, and -58).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12198606     DOI: 10.1086/342972

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population.

Authors:  M Paz Cañadas; F Xavier Bosch; M Luisa Junquera; Maijo Ejarque; Rebeca Font; Elena Ordoñez; Silvia de Sanjosé
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

2.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Authors:  Mahboobeh Safaeian; Koen Quint; Mark Schiffman; Ana Cecilia Rodriguez; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Raphael P Viscidi; Wim Quint; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-11-23       Impact factor: 13.506

3.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

4.  Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.

Authors:  Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

5.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

6.  Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV.

Authors:  Zainab A Malik; Susan M Hailpern; Robert D Burk
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

7.  Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Authors:  Yevgeniy Y Studentsov; Gloria Y F Ho; Morgan A Marks; Robert Bierman; Robert D Burk
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.

Authors:  Tsung-Chieh Jane Fu; Joseph J Carter; James P Hughes; Qinghua Feng; Stephen E Hawes; Stephen M Schwartz; Long Fu Xi; Taylor Lasof; Joshua E Stern; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2016-08-04       Impact factor: 7.396

9.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

10.  Model for assessing human papillomavirus vaccination strategies.

Authors:  Elamin H Elbasha; Erik J Dasbach; Ralph P Insinga
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.